These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 18936548)

  • 1. Current approaches to optimizing the treatment of endometriosis in adolescents.
    Laufer MR
    Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-back therapy in the treatment of endometriosis-associated pain.
    Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
    Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Add-back" therapy for endometriosis in adolescents.
    Lubianca JN; Gordon CM; Laufer MR
    J Reprod Med; 1998 Mar; 43(3):164-72. PubMed ID: 9564639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
    Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
    Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of GnRH agonist therapy. Review of clinical studies and their implications.
    Agarwal SK
    J Reprod Med; 1998 Mar; 43(3 Suppl):293-8. PubMed ID: 9564664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone densitometry as an adjunct to GnRH agonist therapy.
    Cann CE
    J Reprod Med; 1998 Mar; 43(3 Suppl):321-30. PubMed ID: 9564668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH analogs: options for endometriosis-associated pain treatment.
    Batzer FR
    J Minim Invasive Gynecol; 2006; 13(6):539-45. PubMed ID: 17097577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of endometriosis.
    Saltiel E; Garabedian-Ruffalo SM
    Clin Pharm; 1991 Jul; 10(7):518-31. PubMed ID: 1830521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment.
    Barbieri RL
    J Reprod Med; 1998 Mar; 43(3 Suppl):287-92. PubMed ID: 9564663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-back therapy in the treatment of endometriosis: the European experience.
    Edmonds DK
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density?
    Agarwal SK
    J Reprod Med; 2002 Jul; 47(7):530-4. PubMed ID: 12170527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
    Chwalisz K; Surrey E; Stanczyk FZ
    Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
    Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
    BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of GnRH agonists plus add-back therapy in the treatment of endometriosis.
    Gargiulo AR; Hornstein MD
    Semin Reprod Endocrinol; 1997; 15(3):273-84. PubMed ID: 9383836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human issues and medical economics of endometriosis. Three- vs. six-month GnRH-agonist therapy.
    Heinrichs WL; Henzl MR
    J Reprod Med; 1998 Mar; 43(3 Suppl):299-308. PubMed ID: 9564665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain.
    Bedaiwy MA; Casper RF
    Fertil Steril; 2006 Jul; 86(1):220-2. PubMed ID: 16716325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
    Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.